Department of Obstetrics and Gynecology, Shandong University Qilu Hospital, Jinan, China.
J Obstet Gynaecol. 2023 Dec;43(1):2171282. doi: 10.1080/01443615.2023.2171282.
Without taking into account existing biomarkers like genetic mutations (BRCA mutation, Homologous recombination deficiency) with advanced ovarian cancer (OC), the overall survival (OS), progress-free survival (PFS) of the aggregate all groups that have been classified were hazard ratio (HR): 0.72, 95% confidence intervals (CI): 0.66-0.79 and HR: 0.48, 95%CI: 0.44-0.52, respectively. Meanwhile, the OS and PFS of the whole population (regardless of existing genetic mutation markers) were HR: 0.74, 95%CI: 0.64-0.87 and HR: 0.52, 95%CI: 0.42-0.65, separately. Furthermore, the OS and PFS of positive gene mutation markers were HR: 0.71, 95%CI: 0.61-0.83 (HRD and BRACm) and HR: 0.47, 95%CI: 0.42-0.52 (HRD and BRACm), individually. The poly ADP-ribose polymers (PARP) inhibitors have desired efficiency and security in the maintenance treatment of advanced OC patients with BRCAm or BRCAwt, HRD or HRP and unknown gene status.
对于晚期卵巢癌（OC），如果不考虑现有的生物标志物（如基因突变（BRCA 突变、同源重组缺陷）），已经分类的所有组别的总生存期（OS）和无进展生存期（PFS）的危险比（HR）分别为 0.72，95%置信区间（CI）为 0.66-0.79 和 HR：0.48，95%CI：0.44-0.52。同时，整个人群（无论是否存在遗传突变标志物）的 OS 和 PFS 分别为 HR：0.74，95%CI：0.64-0.87 和 HR：0.52，95%CI：0.42-0.65。此外，阳性基因突变标志物的 OS 和 PFS 分别为 HR：0.71，95%CI：0.61-0.83（HRD 和 BRACm）和 HR：0.47，95%CI：0.42-0.52（HRD 和 BRACm）。聚 ADP-核糖聚合酶（PARP）抑制剂在 BRCA m 或 BRCAwt、HRD 或 HRP 和未知基因状态的晚期 OC 患者的维持治疗中具有理想的疗效和安全性。
